stockportfolio.pro
Stocks / INCY vs MRNA
INCY vs MRNA
Incyte Corporation and Moderna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Incyte Corporation (INCY) | Moderna, Inc. (MRNA) | |
|---|---|---|
| Market cap | $20.6B | $18.9B |
| Revenue (latest FY) | $5.14B | $1.94B |
| Net income (latest FY) | $1.29B | $-2.82B |
| Revenue growth (5y CAGR) | 14.0% | 19.3% |
| Net margin | 25.0% | -145.2% |
| Return on equity | 24.9% | -32.6% |
| P/E ratio | 14.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 8 | 2 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open INCY — free Open MRNA — freeFrequently asked questions
Which is bigger, INCY or MRNA?
Incyte Corporation is larger by market capitalization — $20.6B versus $18.9B.
Which grows faster, INCY or MRNA?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus 14.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.